How to get retatrutide: clinical trials, expanded access, and the law

The short answer: the only lawful way to get retatrutide today is to enroll in a registered clinical trial. A small pre-approval expanded access program exists for adults with severe, treatment-resistant obesity, but a physician has to request it. Retatrutide is not FDA approved, no pharmacy can lawfully compound it, and the manufacturer describes it as a molecule that cannot be legally sold or marketed for human use. [1]

That leaves many people who search "how to get retatrutide" with a real problem: they want strong weight loss now. The approved drugs in the same family, tirzepatide and semaglutide, are available by prescription, and this guide ends with how to reach them. It does not cover dosing.

Where can you get retatrutide legally?

Retatrutide is investigational. In its own trial announcements, the manufacturer states that the drug is legally available only to participants in its clinical trials. [2] That rules out every other channel in the United States:

• Pharmacies: there is no approved product to dispense.
• Compounding pharmacies and outsourcing facilities: FDA states that retatrutide cannot be used in compounding under federal law, because it is not a component of an FDA-approved drug and has not been found safe and effective for any condition. [6] It does not appear on the 503A bulk substance lists. [7]
• Telehealth: FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, including direct marketing to consumers. [6]

The legal detail is logged on the retatrutide regulatory tracker, and our legal hub explains how federal and state rules apply to peptides generally.

How to find a retatrutide clinical trial

ClinicalTrials.gov is the federal registry of clinical studies, and it lists the retatrutide studies, including the phase 3 program. On September 23, 2026, a search for retatrutide as the intervention returned 33 records: 21 completed, 9 active but no longer recruiting, 2 recruiting, and 1 expanded access record marked available. [3] Most of the large phase 3 trials have finished enrolling, so openings are limited.

How to search:

1. Go to ClinicalTrials.gov and enter "retatrutide" in the intervention or treatment field. The code name LY3437943 finds the same studies.
2. Filter the recruitment status to "Recruiting" or "Not yet recruiting".
3. Open each listing and read the eligibility criteria: age, BMI range, whether diabetes is required or excluded, and conditions that rule people out.
4. Check the locations section for sites near you and use the listed contact for that site.
5. Ask the study team what the trial involves before you agree to anything. Useful questions: how many visits, how long the trial lasts, whether there is a placebo group, and what happens when the study ends.

Two things to expect. Many trials randomize some participants to placebo, so enrolling does not guarantee you will receive the drug. And trial eligibility is strict by design. [3]

Is there early access to retatrutide?

Yes, in a narrow form. The manufacturer has registered a pre-approval expanded access program on ClinicalTrials.gov, marked available and last updated in August 2026. [4] It offers single-patient access for adults who meet all of these criteria: [4]

• Age 18 or older.
• BMI of 35 or higher despite adhering to and tolerating the highest available dose of approved weight management therapy.
• Two or more serious or life-threatening obesity-related complications that are being treated.
• Unable to join an ongoing retatrutide trial or a comparable investigational trial, because of eligibility rules or distance.
• All standard options, including bariatric surgery, discussed through shared decision-making.

Requests are started by the treating physician on the patient's behalf, and the listing asks patients to go through their physician rather than contact the company directly. Availability depends on geography, supply, and individual assessment. [4]

This matches how FDA describes expanded access in general. Sometimes called compassionate use, it is a pathway for a patient with a serious or immediately life-threatening condition to receive an investigational product outside a trial when no comparable or satisfactory alternative exists and trial enrollment is not possible. [5] For most people seeking weight loss, the approved drugs count as a satisfactory alternative, which is why the program is limited to people who have already tried them.

Why online and compounded retatrutide is unlawful

Products sold as retatrutide online fall into two groups, and both are unlawful for human use.

"Research" products. FDA has warned companies that sold unapproved drugs containing retatrutide, labeled "for research purposes" or "not for human consumption," directly to consumers for human use with dosing instructions. The agency urges consumers not to buy these products, which are of unknown quality and may be harmful. [6] A 2026 case report described a man with type 1 diabetes hospitalized with vomiting, high ketones, and acute kidney injury after injecting an online product sold as retatrutide; a gut infection was also present, and the authors pointed to uncertain composition and dosing as part of the risk. [8]

"Compounded" products. No lawful compounded retatrutide exists. FDA has warned ingredient distributors for selling retatrutide to compounders and outsourcing facilities for repackaging it. [6] Any clinic or site offering it is offering an unapproved drug.

For athletes there is one more rule: retatrutide is prohibited at all times under section S0 of the WADA list, which covers substances without government approval for human use. [9]

What's actually offered, and what that means for you

Retatrutide is openly advertised online, and some clinics and telehealth prescribers offer it alongside compounded peptides. That does not make it lawful. Retatrutide is not FDA approved, is not a component of an approved drug, and is not on the 503A bulks list, so no pharmacy has a lawful basis to compound it. [7] In August 2026 FDA warned an online seller whose "research use only" products included retatrutide. [15]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, its Category 2 safety list, and import alerts that let it detain peptide shipments, including an alert on GLP-1 bulk substances that names retatrutide, rather than stopping every pharmacy. [12] [13] [14] [15] [16] State boards of pharmacy oversee pharmacies day to day, and their rules differ. [11]

What changes for you:

• No FDA review of the product. FDA does not verify a compounded drug's safety, effectiveness, or quality before it is sold. [11]
• Identity, purity, sterility, and dose accuracy vary. FDA warns that unapproved GLP-1 products may contain the wrong ingredient or amount. [6]
• Insurance rarely pays, because there is no approved indication to match, so you usually pay cash.
• Sport. Retatrutide is prohibited at all times under WADA section S0. [9]

If someone offers you retatrutide, look for a 503A pharmacy licensed in your state, a real evaluation by a licensed prescriber rather than an online form, and a certificate of analysis for the specific batch. These checks lower some risks, but they do not make an unlawfully compounded product lawful or safe. The approved alternatives are GLP-1 drugs such as tirzepatide and semaglutide, prescribed for weight management; the GLP-1 hub lists them. [10]

What does retatrutide cost?

Retatrutide has no lawful price because it is not on the market; see retatrutide cost for approved GLP-1 prices as a reference point. If you enroll in a trial, ask the study team what the protocol provides and whether any costs fall to you; each ClinicalTrials.gov listing names a contact for every site. [3]

Lawful options while retatrutide is in trials

If you are weighing retatrutide for weight or blood sugar, approved drugs are available now through a prescriber, with FDA-reviewed labels and known safety data. Tirzepatide, a dual GIP and GLP-1 agonist, produced a mean weight change of minus 20.9% at 72 weeks on its top dose in its pivotal obesity trial, versus minus 3.1% on placebo. [10] Our tirzepatide vs retatrutide comparison shows how the two programs line up, with the caveat that no published trial has compared them directly.

Next steps:

• The GLP-1 hub lists every approved drug in the class with regulatory status and cost.
• How to get peptides prescribed explains the lawful prescription path, and what is peptide therapy explains what legitimate clinics can and cannot offer.
• Zepbound vs Mounjaro covers the two tirzepatide brands and why coverage differs.
• The compounded tirzepatide guide explains when compounding is still lawful for approved molecules.
• The obesity condition page grades every option we track.

For the trial results themselves, see retatrutide before and after, retatrutide side effects, and where the phase 3 program stands.